Ovarian Neoplasms
271
42
57
129
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
51 trials with published results (19%)
Research Maturity
129 completed trials (48% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
14.8%
40 terminated out of 271 trials
76.3%
-10.2% vs benchmark
11%
29 trials in Phase 3/4
40%
51 of 129 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 129 completed trials
Clinical Trials (271)
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Phase I Platinum Based Chemotherapy Plus Indomethacin
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Prospective Sample Collection Study for a Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors